Literature DB >> 30410126

Functional cure of HIV: the scale of the challenge.

Miles P Davenport1, David S Khoury2, Deborah Cromer2, Sharon R Lewin3,4, Anthony D Kelleher2, Stephen J Kent3,4,5,6.   

Abstract

A variety of interventions to induce a functional cure of HIV are being explored, with the aim being to allow patients to cease antiretroviral therapy (ART) for prolonged periods of time or for life. These interventions share the goal of inducing ART-free remission from HIV pathogenesis and disease progression but achieve this in quite different ways, by reducing the size of the latent reservoir (for example, small-molecule stimulation of latently infected cells), reducing the number of target cells available for the virus (for example, gene therapy) or improving immune responses (for example, active or passive immunotherapy). Here, we consider a number of these alternative strategies for inducing post-treatment control of HIV and use mathematical modelling to predict the scale of the challenge inherent in these different approaches. For many approaches, over 99.9% efficacy will likely be required to induce durable ART-free remissions. The efficacy of individual approaches is currently far below what we predict will be necessary, and new technologies to achieve lifelong functional cure are needed.

Entities:  

Year:  2019        PMID: 30410126     DOI: 10.1038/s41577-018-0085-4

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  36 in total

1.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

2.  Virtual memory CD8+ T cells restrain the viral reservoir in HIV-1-infected patients with antiretroviral therapy through derepressing KIR-mediated inhibition.

Authors:  Jie-Hua Jin; Hui-Huang Huang; Ming-Ju Zhou; Jing Li; Wei Hu; Lei Huang; Zhe Xu; Bo Tu; Guang Yang; Ming Shi; Yan-Mei Jiao; Xing Fan; Jin-Wen Song; Ji-Yuan Zhang; Chao Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2020-03-24       Impact factor: 11.530

Review 3.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

Review 4.  Why and where an HIV cure is needed and how it might be achieved.

Authors:  Thumbi Ndung'u; Joseph M McCune; Steven G Deeks
Journal:  Nature       Date:  2019-12-18       Impact factor: 49.962

5.  PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients.

Authors:  Julien Pothlichet; Thierry Rose; Florence Bugault; Louise Jeammet; Annalisa Meola; Ahmed Haouz; Frederick Saul; David Geny; José Alcami; Ezequiel Ruiz-Mateos; Luc Teyton; Gérard Lambeau; Jacques Thèze
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

6.  Predictors of SIV recrudescence following antiretroviral treatment interruption.

Authors:  Mykola Pinkevych; Christine M Fennessey; Deborah Cromer; Carolyn Reid; Charles M Trubey; Jeffrey D Lifson; Brandon F Keele; Miles P Davenport
Journal:  Elife       Date:  2019-10-25       Impact factor: 8.140

7.  Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques.

Authors:  Peter Abbink; Noe B Mercado; Joseph P Nkolola; Rebecca L Peterson; Hubert Tuyishime; Katherine McMahan; Edward T Moseley; Erica N Borducchi; Abishek Chandrashekar; Esther A Bondzie; Arshi Agarwal; Aaron J Belli; Keith A Reimann; Brandon F Keele; Romas Geleziunas; Mark G Lewis; Dan H Barouch
Journal:  Science       Date:  2019-09-05       Impact factor: 47.728

8.  Novel PF74-like small molecules targeting the HIV-1 capsid protein: Balance of potency and metabolic stability.

Authors:  Lei Wang; Mary C Casey; Sanjeev Kumar V Vernekar; Rajkumar Lalji Sahani; Karen A Kirby; Haijuan Du; Huanchun Zhang; Philip R Tedbury; Jiashu Xie; Stefan G Sarafianos; Zhengqiang Wang
Journal:  Acta Pharm Sin B       Date:  2020-07-31       Impact factor: 11.413

Review 9.  Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.

Authors:  Lu Zheng; Camlin Tierney; Ronald J Bosch
Journal:  Curr HIV/AIDS Rep       Date:  2021-07-02       Impact factor: 5.495

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.